TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03523572

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab is an aqueous solution formulated at 10 mg/mL to be administered at a flat dose of 360 mg IV over 30 minutes. Protocol-defined thyroid testing is required while taking nivolumab.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab is an aqueous solution formulated at 10 mg/mL to be administered at a flat dose of 360 mg IV over 30 minutes. Protocol-defined thyroid testing is required while taking nivolumab.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab is an aqueous solution formulated at 10 mg/mL to be administered at a flat dose of 360 mg IV over 30 minutes. Protocol-defined thyroid testing is required while taking nivolumab.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab is an aqueous solution formulated at 10 mg/mL to be administered at a flat dose of 360 mg IV over 30 minutes. Protocol-defined thyroid testing is required while taking nivolumab.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab is an aqueous solution formulated at 10 mg/mL to be administered at a flat dose of 360 mg IV over 30 minutes. Protocol-defined thyroid testing is required while taking nivolumab.
Study: NCT02790515

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Given IV prior to transplant on Day -1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Given oral (PO) or IV beginning prior to transplant on Day -2. The dose will begin to taper at approximately day +60 after transplant in the absence of GVHD. Tacrolimus was used for the first 5 participants enrolled on study. Subsequent participants receive sirolimus.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thiotepa
Description: Given IV prior to transplant on Day -3.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HPC,A Infusion
Description: Hematopoietic Progenitor Cell, Apheresis (HPC,A) infusion of TCRɑβ+ depleted cells on day of transplant (Day 0) and HPC,A infusion of CD45RA+ depleted cells on Day +1 following transplant.
Study: NCT02932176

Intervention type: DEVICE
Intervention: Non-invasive vascular testing
Description: Results of clinically indicated non-invasive vascular testing will be used to develop a machine learning algorithm

Intervention type: DEVICE
Intervention: machine-learning algorithm
Study: NCT02790515

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CliniMACS
Description: The mechanism of action of the CliniMACS Cell Selection System is based on magnetic-activated cell sorting (MACS). The CliniMACS device is a powerful tool for the isolation of many cell types from heterogeneous cell mixtures, (e.g. apheresis products). These can then be separated in a magnetic field using an immunomagnetic label specific for the cell type of interest, such as CD3+ human T cells.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: Given orally (PO) starting Day 0. The dose will be tapered off over two weeks starting on Day +42 in the absence of GVHD.
Study: NCT01006239

Intervention type: OTHER
Intervention: No study intervention
Description: The is no study related intervention.
Study: NCT04537195

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ADSMP-C
Description: A transdiagnostic, lay-led, group-based self-management program consisting of seven 2 ½ hour weekly sessions focusing on increasing patient self-efficacy in symptom management of anxiety and depression in cancer (ADSMP-C)
Study: NCT03878095

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo tumor biopsies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Aspiration
Description: Undergo bone marrow aspiration and biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Biopsy
Description: Undergo bone marrow aspiration and biopsy
Study: NCT03195348

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HBF Bed Rest
Description: 7 days of bed rest on hyper-buoyancy floatation (HBF)
Study: NCT00442442

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: mosquito coils
Description: mosquito coil / night mosquito coil \& LLIN / night
Study: NCT03878095

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ceralasertib
Description: Given PO

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT scans

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI scans

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: Given PO
Study: NCT00179465

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tiagabine
Description: Up to 36 mg daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT00739362

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcranial Direct Current Stimulation (TDCS)
Description: Active tDCS (anodal left DLPFC)
Study: NCT04846933

Intervention type: GENETIC
Group type: OTHER
Intervention: WGS and RNA sequencing

Intervention type: GENETIC
Group type: OTHER
Intervention: WGS and RNA sequencing

Intervention type: GENETIC
Group type: OTHER
Intervention: circulating tumor DNA (ctDNA)

Intervention type: GENETIC
Group type: OTHER
Intervention: circulating tumor DNA (ctDNA)
Study: NCT04846933

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: FDG PET/CT imaging

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: FDG PET/CT imaging
Study: NCT00739362

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial Direct Current Stimulation (TDCS)
Description: Active tDCS (anodal left DLPFC)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial Direct Current Stimulation (TDCS)
Description: Active tDCS (anodal left DLPFC)
Study: NCT00442442

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: LLIN
Description: Sleep under LLIN every night
Study: NCT02703012

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Adjustment of ventilator settings by EIT
Description: Diagnostic maneuvers (change in tidal volume, recruitment maneuvers) will be performed to detect overdistention, tidal recruitment and recruitability. Tidal volume will be reduced if overdistention is detected by EIT. Positive end-expiratory pressure will be increased if tidal recruitment or recruitability are detected.
Study: NCT03905031

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: InfraScanner 2000
Description: The InfraScanner is a portable screening device that measures lateralized differences in optical density (OD) to determine the presence of intracranial hematoma. A difference in OD\>0.2 is abnormal and suggestive of intracranial hematoma.
Study: NCT00919750

Intervention type: OTHER
Intervention: Cytology Specimen Collection Procedure
Description: Correlative studies
Study: NCT00394251

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adriamycin and Cytoxan (AC)
Description: Adriamycin (doxorubicin) and Cytoxan (cyclophosphamide) make up the chemotherapy regimen known as AC. Adriamycin 60 mg/m\^2 intravenous, plus Cytoxan 600 mg/m\^2 intravenous on Day 1 of each of four 2-week cycles (weeks 1-8).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adriamycin and Cytoxan (AC)
Description: Adriamycin (doxorubicin) and Cytoxan (cyclophosphamide) make up the chemotherapy regimen known as AC. Adriamycin 60 mg/m\^2 intravenous, plus Cytoxan 600 mg/m\^2 intravenous on Day 1 of each of four 2-week cycles (weeks 1-8).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABI-007
Description: 260 mg/m\^2 IV on day 1 of each of four 2-week cycle, representing treatment cycles 5-8 (weeks 9-16)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Taxol
Description: 175 mg/m\^2 intravenously (IV) on day 1 of each of four 2-week cycle, representing treatment cycles 5-8 (weeks 9-16)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: 10 mg/kg on day 1 of each of eight 2-week cycles (weeks 9-16), then 15 mg/kg on day 1 of each of ten three-week cycles (weeks 17-46).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: 10 mg/kg on day 1 of each of eight 2-week cycles (weeks 9-16), then 15 mg/kg on day 1 of each of ten three-week cycles (weeks 17-46).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pegfilgrastim
Description: 6 mg subcutaneous (SC) on day 2 for each of the first four 2-week cycles (weeks 1-8). Pegfilgrastim 6 mg SC was administered on day 2 of cycles 6-8 (weeks 11-16) during taxane treatment only if necessary.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pegfilgrastim
Description: 6 mg subcutaneous (SC) on day 2 for each of the first four 2-week cycles (weeks 1-8). Pegfilgrastim 6 mg SC was administered on day 2 of cycles 6-8 (weeks 11-16) during taxane treatment only if necessary.
Study: NCT00588172

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Metformin
Description: 1000mg bid for 1 week
Study: NCT00739362

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham/no-stimulation
Description: Sham tDCS

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham/no-stimulation
Description: Sham tDCS
Study: NCT04449198

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Resveratrol
Description: 500 mg of oral trans-resveratrol twice daily (in the morning and evening) for 12-weeks

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: placebo for 12 weeks
Study: NCT03803774

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Birinapant
Description: Given IV

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity-Modulated Radiation Therapy
Description: Undergo IMRRT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tumor Biopsy
Description: Baseline and cycle 1 day 4 at week 1.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: PET Scan
Description: Within 6 weeks pre-treatment, +/- 2 weeks 3 months post radiation treatment, and +/- 4 weeks at 6, 9,12,18 and 24 months post radiation treatment.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: CT Scan
Description: CT scan of the neck, chest, and upper abdomen with contrast at 6 weeks pre-treatment, +/- 2 weeks 3 months post radiation treatment, and +/- 4 weeks at 6, 9,12,18 and 24 months post radiation treatment.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: MRI Scan
Description: MRI scan of the neck, chest, and upper abdomen with contrast at 6 weeks pre-treatment, +/- 2 weeks 3 months post radiation treatment, and +/- 4 weeks at 6, 9,12,18 and 24 months post radiation treatment.
Study: NCT04285814

Intervention type: DIAGNOSTIC_TEST
Intervention: Whole Fetal Cell (WFC) Testing
Description: Performing WFC testing on blood specimens.

Intervention type: DIAGNOSTIC_TEST
Intervention: Whole Fetal Cell (WFC) Testing
Description: Performing WFC testing on blood specimens.
Study: NCT03223610

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Administered orally, days 2-14, at varying doses of 200-800 mg (based upon assigned dose level); every 21 days for up to 6 cycles, or until disease progression or unacceptable toxicity
Study: NCT00588172

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: 1000mg bid for 1 week
Study: NCT02687529

Intervention type: DEVICE
Intervention: CST001
Study: NCT03692052

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AG-348
Description: AG-348 tablet orally BID
Study: NCT04362085

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Therapeutic Anticoagulation
Description: The choice of low molecular weight heparin (LMWH) versus unfractionated heparin (UFH) will be at the clinician's discretion. LMWH options include: Tinzaparin, Enoxaparin or Dalteparin. UFH will be administered using a weight-based nomogram with titration according to center-specific institutional protocol.
Study: NCT04608123

Intervention type: OTHER
Intervention: none (observational study)
Description: DBS
Study: NCT00788320

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D3
Description: Vitamin D3 50,000 IU three times a week for 8 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo three times a week for 8 weeks
Study: NCT04576130

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Implantable cardioverter defibrillator
Description: Implantation of an ICD for secondary prevention
Study: NCT04023370

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Treatment of primary iliac artery stenosis and/or occlusive lesions
Description: Stent implantation

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Treatment of primary iliac artery stenosis and/or occlusive lesions
Description: Stent implantation
Study: NCT05100836

Intervention type: DEVICE
Intervention: Impella 5.5
Description: Impella 5.5 mechanical circulatory support
Study: NCT03198650

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acalabrutinib
Description: Acalabrutinib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acalabrutinib
Description: Acalabrutinib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: Obinutuzumab
Study: NCT03065062

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib
Description: Palbociclib will be administered orally once daily, 3 weeks out of every 4 in each cycle. The initial dose for part 1 of the study will be 100 mg daily. Dosing will be adjusted until Maximum Tolerated Dose (MTD) and the Recommended Phase 2 Dose (RP2D) are established. No pre-medications for palbociclib are required. It should be administered with food.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gedatolisib
Description: Gedatolisib will be administered once weekly on the first day for each of the four weeks during the 4-week cycle. The initial dose for part 1 of the study will be 110 mg. Dosing will be adjusted until Maximum Tolerated Dose (MTD) and the Recommended Phase 2 Dose (RP2D) are established. No pre-medications for gedatolisib are required.
Study: NCT03321045

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [89Zr]-Df-Trastuzumab
Description: \[89Zr\]-Df-Trastuzumab will be administered intravenously. The administered dose will be 2 mCi at the time of injection. The amount of injected drug is 5 mg of Trastuzumab.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: PET/MRI Imaging
Description: 5-6 days post injection the patients will undergo PET/MRI imaging.
Study: NCT03125070

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Best Practice and Internet site with links to existing resources
Description: Receive usual care

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Internet, Mobile app and Telehealth Intervention
Description: Receive INSPIRE and survivorship care plan

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Survey Administration
Description: Ancillary studies
Study: NCT04149990

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Entresto Pill
Description: NO other interventions

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Entresto Pill
Description: NO other interventions
Study: NCT02747004

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abemaciclib
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abemaciclib
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abemaciclib
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamoxifen
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prophylactic Loperamide
Description: Administered orally
Study: NCT02911103

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: DBS surgery
Description: Unilateral thalamic DBS therapy

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Medtronic Activa Rechargeable System
Description: Used for diagnostic purposes.
Study: NCT02203526

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isavuconazole
Description: Isavuconazole to begin at least 3 days prior to ibrutinib and continue throughout chemotherapy (cycles 1-6)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isavuconazole
Description: Isavuconazole to begin at least 3 days prior to ibrutinib and continue throughout chemotherapy (cycles 1-6)
Study: NCT00590174

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: stopping clopidogrel at 1 year after DES implantation
Study: NCT02203526

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isavuconazole
Description: Isavuconazole to begin at least 3 days prior to ibrutinib and continue throughout chemotherapy (cycles 1-6)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TEDDI
Description: Temozolomide, etoposide, doxil, dexamthasone, ibrutinib (TEDDI) given every 21 days for cycles 2-6 (Arm 1-A); given every 21 days for cycles 1-6 (Arms 1-B, 2, 3 and 4)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TEDDI
Description: Temozolomide, etoposide, doxil, dexamthasone, ibrutinib (TEDDI) given every 21 days for cycles 2-6 (Arm 1-A); given every 21 days for cycles 1-6 (Arms 1-B, 2, 3 and 4)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TEDDI
Description: Temozolomide, etoposide, doxil, dexamthasone, ibrutinib (TEDDI) given every 21 days for cycles 2-6 (Arm 1-A); given every 21 days for cycles 1-6 (Arms 1-B, 2, 3 and 4)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TEDDI
Description: Temozolomide, etoposide, doxil, dexamthasone, ibrutinib (TEDDI) given every 21 days for cycles 2-6 (Arm 1-A); given every 21 days for cycles 1-6 (Arms 1-B, 2, 3 and 4)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TEDDI
Description: Temozolomide, etoposide, doxil, dexamthasone, ibrutinib (TEDDI) given every 21 days for cycles 2-6 (Arm 1-A); given every 21 days for cycles 1-6 (Arms 1-B, 2, 3 and 4)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab (R) given with TEDD and TEDDI every 3 weeks for cycles 1-6 (all arms)
Study: NCT00590174

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin,Clopidogrel
Description: continue aspirin and clopidogrel 1year after DES
Study: NCT02203526

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab (R) given with TEDD and TEDDI every 3 weeks for cycles 1-6 (all arms)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab (R) given with TEDD and TEDDI every 3 weeks for cycles 1-6 (all arms)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab (R) given with TEDD and TEDDI every 3 weeks for cycles 1-6 (all arms)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab (R) given with TEDD and TEDDI every 3 weeks for cycles 1-6 (all arms)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Cytarabine given via Ommaya reservoir (IT therapy) on days 1 and day 5 of cycles 2-6 (all arms)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Cytarabine given via Ommaya reservoir (IT therapy) on days 1 and day 5 of cycles 2-6 (all arms)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Cytarabine given via Ommaya reservoir (IT therapy) on days 1 and day 5 of cycles 2-6 (all arms)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Cytarabine given via Ommaya reservoir (IT therapy) on days 1 and day 5 of cycles 2-6 (all arms)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Cytarabine given via Ommaya reservoir (IT therapy) on days 1 and day 5 of cycles 2-6 (all arms)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TEDD
Description: Temozolomide, etoposide, doxil, dexamthasone, (TEDD) given on first cycle (Arm 1-A)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib (Arms 2, 3 and 4)
Description: Ibrutinib given on day -3 to day -1 on cycle 1 (Arms 2, 3 and 4)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Methotrexate on days 1 and day 5 of cycles 2-6 (Arm 4)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib (Arm 1 - Closed with Amendment G)
Description: Ibrutinib given on day -14 to day -1 on cycle 1 (Arm 1)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib (Arm 4)
Description: Ibrutinib given on days 1-10 for cycles 1-6 (Arm 4)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib (Arm 4)
Description: Ibrutinib given on days 1-10 for cycles 1-6 (Arm 4)
Study: NCT00065676

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quercetin
Description: 1 or 2 grams of quercetin or placebo will be given while patients undergo 6-hour OGTT

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quercetin
Description: 1 or 2 grams of quercetin or placebo will be given while patients undergo 6-hour OGTT

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Study: NCT01326156

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Knee arthroplasty
Description: Comparison of patellofemoral arthroplasty versus conventional total knee arthroplasty in cases of isolated patellofemoral osteoarthritis.
Study: NCT00001452

Intervention type: DRUG
Intervention: oCRH
Study: NCT00646022

Intervention type: DRUG
Intervention: [18F]-DOPA
Description: 18F-DOPA PET/CT Scan.

Intervention type: DRUG
Intervention: [18F]-DOPA
Description: 18F-DOPA PET/CT Scan.
Study: NCT03912428

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: 11C-MC1
Description: PET radioligand for COX-2

Intervention type: DRUG
Group type: OTHER
Intervention: Celecoxib
Description: COX-2 inhibitor